The California Dept. of Public Health along with the Center for Disease Control require masks to be worn in ALL health care facilities. COVID is a respiratory virus; as such all staff, patients and visitors must adhere to this directive at all Riverside Medical Clinic locations. ANYONE who refuses to comply will be asked to leave the facility. Many patients treated at clinics such as RMC have health issues that put them at a higher risk. This mask policy is designed to protect all our patients.
Riverside Medical Clinic’s Clinical Research Closed Research Trials are dedicated to our community with access to cutting-edge medical treatments. By working with pharmaceutical and biotechnology companies, we take part in the latest treatments being developed for the U.S. market.
We specialize in trials in the following areas:
|Infectious Diseases||Chronic Pain||Skin Disorders|
|Migraine Headaches||& More…|
Patient safety and welfare is our first priority. All Enrolling Research Trials conducted at our clinic are FDA monitored and overseen by an Institutional Review Board. Our dedicated team of physicians and staff work together to ensure patient safety and integrity of study data throughout the entire process.
Stallergenes: A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis.
R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 2 –
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 3 –
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
R-Pharm: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4 –
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis.
Shire: A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years with Attention-Deficit/Hyperactivity Disorder (ADHD).
Shire: A Phase 3, Open-label, Multicenter, 12-Month, Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed with Attention-deficit/Hyperactivity Disorder.
Pearl Therapeutics: A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma.
Bristol-Myers Squibb: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sjögrens Syndrome.
CEM-102 Pharmaceuticals, Inc. / “A Randomized, Double-blind, Multi-center Study To Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections”.
Be a part of the solution and begin your new treatment option with the medicine of tomorrow!